Advances in sarcoma genomics and new therapeutic targets.

Abstract excerpt

Increasingly, human mesenchymal malignancies are being classified by the abnormalities that drive their pathogenesis. Although many of these aberrations are highly prevalent within particular sarcoma subtypes, few are currently targeted therapeutically. Indeed, most subtypes of sarcoma are still treated with traditional therapeutic modalities, and in many cases sarcomas are resistant to adjuvant therapies. In...

Topics

Join the communities discussing this publication.

• Antineoplastic Agents
• Genome
• Genomics
• Mice
• Mutation
• Sarcoma